ClinicalTrials.gg
WithdrawnNCT07057479CONTROLUpdated Dec 18, 2025

Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin

A Phase 3 interventional study of Fixed-dose combination of SGLT2 inhibitor and thiazolidinedione and Control Group 1 Intervention - SGLT2 inhibitor monotherapy in Type 2 Diabetes Mellitus (T2DM), sponsored by Eurofarma Laboratorios S.A.. Withdrawn at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by Eurofarma Laboratorios S.A. · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Strategic change in development priorities

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 317 studies in Diabetes Mellitus, Type 2 with a site in Brazil — 36 open to participants now, 45 under way, 22 of them phase 3. Diabetes Mellitus, Type 2 · Brazil.

Enrollment
291st of 295
0 · median 329
Started
2026
with 22 others
Phase 3
150 of 317
18 open now
Registered
292nd of 317
by date

Among the 317 studies in Diabetes Mellitus, Type 2 with a site in Brazil, this one is the 291st largest by enrollment of the 295 interventional ones that give a count, is one of 23 that started in 2026, is one of 150 in phase 3, and was the 292nd registered.

Diabetes Mellitus, Type 2

10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

36 of the 317 studies in Diabetes Mellitus, Type 2 with a site in Brazil are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 317 studies in Diabetes Mellitus, Type 2 with a site in Brazil, or all of them as a file.
02

Study summary

This clinical trial is studying whether combining two commonly used diabetes medications into a single pill works better than taking them separately for people with type 2 diabetes who are already on metformin. Both medications work in different ways to lower blood sugar - one helps remove excess sugar through urine while the other helps the body use insulin better.

The study has two main goals:

To see if the combined pill controls blood sugar more effectively than either medication alone

To check if combining them reduces common side effects like weight gain and swelling that can occur with one of the medications

Participants will be randomly assigned to one of three groups:

The new combination pill

One of the standard diabetes medications alone

The other standard diabetes medication alone

All participants will take their assigned treatment daily and attend regular clinic visits for monitoring. Doctors will track blood sugar control, weight changes, and any side effects throughout the study period.

This research could lead to a simpler treatment option that combines the benefits of both medications while potentially minimizing side effects. For people with diabetes who often need multiple medications, a combined pill might make treatment easier to manage while providing better blood sugar control.

Read the detailed description

This phase III clinical trial investigates a fixed-dose combination (FDC) of two established antidiabetic medications with complementary mechanisms of action: an SGLT2 inhibitor and a thiazolidinedione (TZD). The study aims to evaluate whether combining these medications in a single tablet provides superior glycemic control compared to either medication alone in patients with type 2 diabetes who are already on metformin therapy.

The SGLT2 inhibitor component lowers blood glucose by increasing urinary glucose excretion, while the TZD component improves insulin sensitivity. Previous studies have shown that these drug classes may offer complementary benefits for metabolic control and cardiovascular risk reduction. However, the TZD component has been associated with side effects including fluid retention and weight gain in some patients. This trial will assess whether the combination can maintain the therapeutic benefits of both drugs while potentially reducing TZD-related adverse effects.

The randomized, double-blind, double-dummy design compares three treatment arms: the FDC, SGLT2 inhibitor monotherapy, and TZD monotherapy. The primary endpoint is the change in HbA1c from baseline after 24 weeks of treatment. Secondary endpoints include measures of safety, tolerability, and additional metabolic parameters.

Participants will undergo regular monitoring including blood tests, physical examinations, and safety assessments throughout the study period. The trial includes specific protocols for detecting and managing potential side effects, particularly those related to fluid retention.

This study addresses an important clinical question regarding optimal treatment strategies for type 2 diabetes, particularly the potential advantages of fixed-dose combinations in simplifying treatment regimens while maintaining efficacy and safety. The results may provide evidence for a new therapeutic option that combines the established benefits of these two drug classes while potentially mitigating some limitations of monotherapy approaches.

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)

Keywords

  • Type 2 Diabetes Mellitus
  • T2DM
  • Fixed-dose combination
  • SGLT2 inhibitor
  • Thiazolidinedione
  • Dual therapy
  • Glycemic control
  • Insulin resistance
  • Randomized clinical trial
  • Phase III trial
  • Diabetes treatment
  • Oral antidiabetic drugs
  • Metformin adjunct therapy
  • HbA1c reduction
  • Cardiovascular risk factors
  • Renal protection
  • Diabetes complications
  • Monotherapy comparison
  • Drug combination efficacy
  • Diabetes management
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form
  • Age ≥18 years
  • Diagnosis of type 2 diabetes (T2DM)
  • 7.5-10% while on stable metformin monotherapy (≥1000 mg/day) for ≥12 weeks
  • ≥80% adherence to run-in medication

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes or other specific diabetes types (e.g., monogenic, pancreatic, or drug-induced)
  • Severe hyperglycemia (≥270 mg/dL) or diabetic ketoacidosis in past 12 weeks
  • to study drugs or
  • Pregnancy, lactation, or planning pregnancy
  • Severe diabetic complications (proliferative retinopathy, severe neuropathy)
  • Major cardiovascular events in past 12 weeks (e.g., myocardial infarction, heart failure III/IV)
  • Uncontrolled hypertension (SBP >180 mmHg or DBP >110 mmHg)
  • Moderate/severe renal impairment ( \<45 mL/min/1.73m²)
  • Liver disease (cirrhosis, active hepatitis)
  • History of (except treated skin cancers) in past 5 years
  • Use of non-metformin antidiabetics or weight-loss drugs in past 12 weeks
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Fixed-Dose Combination of SGLT2i /TZD + Metformin

    Participants receive a fixed-dose combination tablet containing two antidiabetic agents (an SGLT2 inhibitor and a thiazolidinedione) once daily, plus matching placebos for both comparator drugs to maintain blinding. All participants continue background metformin therapy (≥1000mg/day). Sample size: 136.

    Drug: Fixed-dose combination of SGLT2 inhibitor and thiazolidinedione · Drug: Background Therapy (All Groups) - Metformin

  • Active comparator
    Control Group 1 - SGLT2 Inhibitor + Metformin

    Participants receive monotherapy with an SGLT2 inhibitor once daily, plus matching placebos for both the FDC and the thiazolidinedione comparator to maintain blinding. All participants continue background metformin therapy (≥1000mg/day). Sample size: 136.

    Drug: Control Group 1 Intervention - SGLT2 inhibitor monotherapy · Drug: Background Therapy (All Groups) - Metformin

  • Active comparator
    Control Group 2 - Thiazolidinedione + Metformin

    Participants receive monotherapy with a thiazolidinedione once daily, plus matching placebos for both the FDC and the SGLT2 inhibitor comparator to maintain blinding. All participants continue background metformin therapy (≥1000mg/day). Sample size: 136.

    Drug: Control Group 2 Intervention - Thiazolidinedione monotherapy · Drug: Background Therapy (All Groups) - Metformin

Interventions

  • DrugFixed-dose combination of SGLT2 inhibitor and thiazolidinedione

    Oral fixed-dose combination tablet containing an SGLT2 inhibitor and a thiazolidinedione, administered once daily. Participants also receive matching placebos for both comparator drugs to maintain blinding. All participants continue background metformin therapy (≥1000mg/day).

  • DrugControl Group 1 Intervention - SGLT2 inhibitor monotherapy

    Oral tablet containing an SGLT2 inhibitor, administered once daily. Participants also receive matching placebos for both the fixed-dose combination and the thiazolidinedione comparator to maintain blinding. All participants continue background metformin therapy (≥1000mg/day). This represents standard monotherapy for comparison against the combination approach.

  • DrugControl Group 2 Intervention - Thiazolidinedione monotherapy

    Oral tablet containing a thiazolidinedione, administered once daily. Participants also receive matching placebos for both the fixed-dose combination and the SGLT2 inhibitor comparator to maintain blinding. All participants continue background metformin therapy (≥1000mg/day). This represents standard monotherapy for comparison against the combination approach.

  • DrugBackground Therapy (All Groups) - Metformin

    Extended-release metformin tablets (≥1000mg daily) continued as background therapy for all participants throughout the study duration.

06

What researchers measure

Primary outcomes

  1. Change in glycated hemoglobin (HbA1c) from baseline to week 24

    Time frame: From baseline to week 24

Secondary outcomes

  1. Proportion of participants achieving HbA1c <7.0% at week 24

    Time frame: At week 24

  2. Change in fasting plasma glucose from baseline to week 24

    Time frame: Baseline to week 24

  3. Incidence of adverse events (AEs) over 24 weeks

    Time frame: Baseline to week 24

  4. Incidence of peripheral edema over 24 weeks

    Time frame: Baseline to week 24

  5. Incidence of moderate/severe hypoglycemia (Level 2/3) over 24 weeks

    Time frame: Baseline to week 24

Other outcomes

  1. Change in body weight from baseline to week 24

    Time frame: Baseline to week 24

07

Study locations

1 site
  • Eurofarma Laboratórios S.A
    Itapevi, São Paulo 06696-000, Brazil
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Feb 2028, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2025
First posted
Jul 9, 2025
StartEst.
Sep 2026
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2028
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07057479
Responsible party
Sponsor
First posted
Jul 9, 2025
Start date
Sep 2026 (estimated)
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Dec 18, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion